Cannabidiol in Patients With Heart Failure Failure in AHA/ACC Stages A-C

NCT03634189 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2020-08-05

No results posted yet for this study

Summary

Cannabidiol in heart failure

Conditions

Interventions

DRUG

Cannabidiol

Patients with ACC/AHA stage A-C will receive 5 mg/kg to a maximum tolerated dose of 25 mg/kg PO BID of Cannabidiol

Sponsors & Collaborators

  • Instituto de Cardiología y Medicina Vascular Hospital Zambrano-Hellion Tec Salud

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
30 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-01
Primary Completion
2021-09-01
Completion
2021-12-01

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03634189 on ClinicalTrials.gov